Shanghai Haohai Biological Technology Co., Ltd. provided unaudited consolidated financial guidance for the nine months ended 30 September 2023. For the period, Group is expected to record an unaudited net profit attributable to shareholders of the Company of approximately RMB 300,000,000 to RMB 330,000,000 during the Reporting Period, representing an increase of approximately RMB 138,250,500 to RMB 168,250,500, or approximately 85.47% to 104.02%, as compared to that in 2022 (corresponding period in 2022: an unaudited net profit attributable to shareholders of the Company of RMB 161,749,504.38). The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB 278,000,000 to RMB 308,000,000, representing an increase of approximately RMB 137,550,600 to RMB 167,550,600, or approximately 97.94% to 119.30%, as compared to that in 2022 (corresponding period in 2022: unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss of RMB 140,449,394.19).